Infusions of Interleukin-1 Alpha After Autologous Transplantation for Hodgkin's Disease and Non-Hodgkin's Lymphoma Induce Effector Cells with Antilymphoma Cytolytic Activity

Overview

Journal J Clin Immunol

Publisher Springer

Specialty Allergy & Immunology

Date 1994 May 1

PMID 7929695

Authors

E Katsanis

D J Weisdorf

Z Xu

B B Dancisak

M L Halet

B R Blazar

Affiliations

Soon will be listed here.

Abstract

We evaluated the cytolytic function, phenotypic characteristics, and cytokine levels of 22 patients with non-Hodgkin's lymphoma and 7 with Hodgkin's disease receiving interleukin-1 alpha (IL-1 alpha) following autologous bone marrow or peripheral blood stem cell transplantation. IL-1 alpha was given i.v. over 6 hr, between day 0 and day +13 posttransplant. On day +14, cells from patients receiving high-dose IL-1 alpha (3.0 micrograms/m2/day) had significantly enhanced killing of natural killer (NK)-sensitive and -resistant lymphoma targets compared to those treated with low-dose IL-1 alpha (0.1, 0.3, or 1.0 microgram/m2/day). The differences in cytolytic function between the two groups persisted but were not as striking on day +28. Patients receiving higher-dose IL-1 alpha had a significantly increased proportion of CD3+ T cells on days +14 and +28, while the proportion of CD16+ and CD56+ NK cells was decreased compared to those of patients treated with the lower dose. There were no detectable levels of IL-2, interferon-gamma, or tumor necrosis factor-alpha in the plasma of patients receiving IL-1 alpha posttransplant. However, higher-dose IL-1 alpha therapy was associated with significant increases in serum IL-6 levels in comparison to those in patients receiving low-dose IL-1 alpha. IL-1 alpha may increase cytolytic function post-bone marrow transplantation; it remains to be determined, however, whether this would have an impact on decreasing relapse rates of patients undergoing transplantation for lymphoma.

References

Houssiau F, Coulie P, Van Snick J . Distinct roles of IL-1 and IL-6 in human T cell activation. J Immunol. 1989; 143(8):2520-4. View

Crump 3rd W, Grimm E . Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells. Cancer Res. 1989; 49(1):149-53. View

Onozaki K, Matsushima K, Kleinerman E, Saito T, Oppenheim J . Role of interleukin 1 in promoting human monocyte-mediated tumor cytotoxicity. J Immunol. 1985; 135(1):314-20. View

Takai Y, Wong G, Clark S, Burakoff S, Herrmann S . B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. J Immunol. 1988; 140(2):508-12. View

Soiffer R, Murray C, Cochran K, Cameron C, Wang E, Schow P . Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood. 1992; 79(2):517-26. View

Sironi M, Breviario F, Proserpio P, Biondi A, Vecchi A, Van Damme J . IL-1 stimulates IL-6 production in endothelial cells. J Immunol. 1989; 142(2):549-53. View

Platanias L, Vogelzang N . Interleukin-1: biology, pathophysiology, and clinical prospects. Am J Med. 1990; 89(5):621-9. DOI: 10.1016/0002-9343(90)90181-c. View

Ben Aribia M, Leroy E, Lantz O, Metivier D, Autran B, Charpentier B . rIL 2-induced proliferation of human circulating NK cells and T lymphocytes: synergistic effects of IL 1 and IL 2. J Immunol. 1987; 139(2):443-51. View

Lovett D, Kozan B, Hadam M, Resch K, Gemsa D . Macrophage cytotoxicity: interleukin 1 as a mediator of tumor cytostasis. J Immunol. 1986; 136(1):340-7. View

10.

Kaye J, Janeway Jr C . Induction of receptors for interleukin 2 requires T cell Ag:Ia receptor crosslinking and interleukin 1. Lymphokine Res. 1984; 3(4):175-82. View

11.

Armitage J . Bone marrow transplantation in the treatment of patients with lymphoma. Blood. 1989; 73(7):1749-58. View

12.

Higuchi C, Thompson J, Petersen F, Buckner C, Fefer A . Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood. 1991; 77(12):2561-8. View

13.

Meyers J, Flournoy N, Sanders J, McGuffin R, Newton B, Fisher L . Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. Ann Intern Med. 1987; 107(6):809-16. DOI: 10.7326/0003-4819-107-6-809. View

14.

Falk W, Mannel D, Darjes H, Krammer P . IL-1 induces high affinity IL-2 receptor expression of CD4-8- thymocytes. J Immunol. 1989; 143(2):513-7. View

15.

Renauld J, Vink A, Van Snick J . Accessory signals in murine cytolytic T cell responses. Dual requirement for IL-1 and IL-6. J Immunol. 1989; 143(6):1894-8. View

16.

Nakamura S, Nakata K, Kashimoto S, Yoshida H, Yamada M . Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors. Jpn J Cancer Res. 1986; 77(8):767-73. View

17.

Klingemann H, Grigg A, Barnett M, Eaves A, Reece D, Shepherd J . Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected]. Blood. 1991; 78(12):3306-11. View

18.

Gutterman J, Grimm E . Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res. 1988; 48(4):788-92. View

19.

Blaise D, Olive D, Stoppa A, Viens P, Pourreau C, Lopez M . Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood. 1990; 76(6):1092-7. View

20.

Ciolli V, Gabriele L, Sestili P, Varano F, Proietti E, GRESSER I . Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases. J Exp Med. 1991; 173(2):313-22. PMC: 2118774. DOI: 10.1084/jem.173.2.313. View